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Zebrafish as a Model to Investigate 
Dynamin 2-Related Diseases
Cinzia Bragato1, Germano Gaudenzi2, Flavia Blasevich1, Giulio Pavesi2, Lorenzo Maggi1, 
Michele Giunta1, Franco Cotelli2 & Marina Mora1
Mutations in the dynamin-2 gene (DNM2) cause autosomal dominant centronuclear myopathy (CNM) 
and dominant intermediate Charcot-Marie-Tooth (CMT) neuropathy type B (CMTDIB). As the relation 
between these DNM2-related diseases is poorly understood, we used zebrafish to investigate the 
effects of two different DNM2 mutations. First we identified a new alternatively spliced zebrafish 
dynamin-2a mRNA (dnm2a-v2) with greater similarity to human DNM2 than the deposited sequence. 
Then we knocked-down the zebrafish dnm2a, producing defects in muscle morphology. Finally, we 
expressed two mutated DNM2 mRNA by injecting zebrafish embryos with human mRNAs carrying 
the R522H mutation, causing CNM, or the G537C mutation, causing CMT. Defects arose especially in 
secondary motor neuron formation, with incorrect branching in embryos injected with CNM-mutated 
mRNA, and total absence of branching in those injected with CMT-mutated mRNA. Muscle morphology 
in embryos injected with CMT-mutated mRNA appeared less regularly organized than in those injected 
with CNM-mutated mRNA. Our results showing, a continuum between CNM and CMTDIB phenotypes 
in zebrafish, similarly to the human conditions, confirm this animal model to be a powerful tool to 
investigate mutations of DNM2 in vivo.
Dynamin-2 (DNM2) related diseases are a heterogeneous group of conditions that affect muscular and nerv-
ous systems. Mutations in DNM2 cause centronuclear myopathy (CNM), a rare hereditary disease character-
ized by centrally located nuclei in muscle fibres. Single (autosomal dominant) mutations in DNM2 occur in 
around 50% of patients with CNM. Other mutations in DNM2 cause the dominant intermediate axonal form of 
Charcot-Marie-Tooth neuropathy type B (hereafter CMT), a motor and sensory neuropathy that primarily affects 
peripheral nerves1–4.
DNM2 belongs to a large family of cytosolic GTPases that act mechanically and enzymatically to mediate 
membrane fission. Dynamins and dynamin-like proteins are involved in the budding off of transport vesicles, in 
organelle division, in cytokinesis and in pathogen resistance5. Dynamin-2 is expressed ubiquitously in mammals, 
dynamin-1 occurs mainly in neurons and dynamin-3 occurs mainly in brain and testes.
Dynamins 1, 2 and 3 have a 5-domain structure: an N-terminal GTPase domain, a middle domain (MD), a 
pleckstrin-homology (PH) domain that binds phosphoinositides, a GTPase effector domain (GED) that (together 
with the MD) is involved in oligomerization and regulation of GTPase activity, and a C-terminal proline-rich 
domain (PRD) that interacts with SH3 domains6.
Mutations in the PH domain of dynamin-2, which specifically binds phosphatidylinositol-4, 5-bisphosphate 
to mediate localization on the membrane, are responsible for severe forms of both CNM and CMT7,8.
Several pathogenic mechanisms related to DNM2 function have been suggested9; however, despite the knowl-
edge gained so far, the pathogenic mechanisms that cause CNM versus CMT are still unknown.
We used zebrafish to investigate and compare the effects of two different DNM2 mutations, one related to 
CNM and one to CMT.
Two co-orthologs of human DNM2 are present in zebrafish, currently named dnm2a and dnm2b (respectively 
dnm2 and dnm2-like for Gibbs et al. 2013): dnm2a is positioned on chromosome 3, while dnm2b is on chro-
mosome 1. They are both expressed throughout early development and in all adult tissues, and are required for 
normal zebrafish development10.
After confirming, by whole mount in situ hybridization (WISH), that dnm2a was the gene linked to the mus-
cular system in zebrafish, but not dnm2b (manuscript in preparation), we noticed that the dnm2a deposited 
sequence was incomplete, and therefore performed in silico analysis. This led us to identify a previously unknown 
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alternatively spliced mRNA sequence of the zebrafish dnm2a, that we called dnm2a-v2, with greater similarity to 
human DNM2 than the deposited sequence, that we called dnm2a-v1.
We next investigated the effects of dnm2a knockdown using two different morpholinos and the effects of res-
cuing the resulting phenotypes by injecting either the dnm2a-v1 or the dnm2a-v2 transcript, through assessment 
of motor behaviour and animal morphology in developing zebrafish embryos.
Finally, and most importantly, we assessed the effects of over-expressing two mutations in the PH domain 
of human dynamin-2, the R522H mutation responsible for CNM, and the G537C mutation responsible for 
CMT. In these CNM and CMT models we evaluated motor behaviour, muscle morphology and motor neuron 
morphology.
Results
Two dnm2a isoforms in zebrafish. Using publicly available sequences (NCBI, ENSEMBL, ZFIN) we iden-
tified a dnm2 transcript that differed from the one previously reported10. The originally identified full-length tran-
script (RefSeq NM_001030128) lacks a 3′ portion corresponding to the last two exons of human DNM2. This was 
surprising given that homologous genes generally have a highly conserved structure (number and size of exons) 
across vertebrate classes. Furthermore, among the ESTs mapping to this locus, several were further spliced and 
extended the 3′ end of the transcript; however only the CV482233 sequence was comparable with the 3′ sequence 
of the human gene found in RefSeq.
We therefore assembled a sequence from the available ESTs to obtain a transcript, deposited in GenBank 
(KC968470), that had greater similarity to the human gene sequence than the initially deposited sequence 
(NM_004945.3). That this sequence was present in vivo was shown by 3′ RACE determinations on zebrafish RNA 
extracted from different stages of development (oocites, 2 cells, 32 cells, 50% epiboly, sphere, 128 cells, 12 somites, 
24 hpf and 4dpf). Since the new transcript was longer than the previously available RefSeq, we called it dnm2a-v2, 
renaming the original RefSeq transcript dnm2a-v1 (Fig. 1). The corresponding proteins were closely similar to 
human dynamin-2: dnm2a-v1 (755 amino acids) was 88% identical, and dnm2a-v2 (856 amino acids) was 87% 
identical. RT-PCR of mRNAs at different developmental stages (Supplementary Fig. 1) showed that, while the 
dnm2a-v1 transcript was present from the earliest stages, dnm2a-v2 was not present before the epiboly stage11,12.
Zebrafish dnm2a expression is related to somite formation. We investigated the spatial localization 
of dnm2a using whole mount in situ hybridization (WISH), using a specific probe recognizing a 456 bp region 
shared by the original dnm2 (dnm2a-v1) and the dnm2a-v2 transcript.
We detected dnm2a from early somitogenesis, 11 hours post fertilization (hpf) approximately, to 30 
somites stage (24 hpf), in specific areas of the CNS and tail (Fig. 2). In the CNS, dnm2a was expressed at the 
midbrain-hindbrain boundary (Fig. 2A,C) and in the bilateral otic vesicles (Fig. 2A,D,E), with a diffuse signal 
in the neural tube, and a strong positivity in the periventricular and in the dorso-lateral portion (Fig. 2F). In the 
tail, dnm2a expression varied with somite maturation. During somitogenesis dnm2a expression was observed 
in paraxial somitic mesoderm and in the adaxial cells, delineating comb-like structures (Fig. 2A,G,H); at 24 hpf 
the transcript appeared in newly formed somites in the tail, progressively disappeared from more rostral somites 
(Fig. 2B and supplementary Fig. 2), and became less intense in the CNS.
To assess whether dnm2a expression was related to somite formation, we performed double staining with 
myf5, a muscle-specific transcription factor that regulates myogenesis13 and is expressed in the paraxial meso-
derm of somites during early embryogenesis14. Dnm2a transcript expression only partially overlapped with myf5 
expression: in dorsal view flat-mounted embryos, dnm2a was expressed in the posterior part of somites and close 
to the notochord, against a background of uniform myf5 expression in somites (Fig. 2G). Transverse sections 
showed that dnm2a was present in the medio-ventral part of the somite and in adaxial cells, while myf5 was 
expressed laterally in fast muscle precursors (Fig. 2H)15.
Morpholino-mediated knockdown of dnm2a in zebrafish. To model the human diseases in zebraf-
ish, we used morpholinos (MO) (Gene Tools Philomath, USA) to block dnm2a translation. Specifically we used 
an antisense oligonucleotide against the start site of the dnm2a transcript (ATGdnm2a-MO), and an MO to 
Figure 1. Full-length dnm2a mRNA. Protein structure of zebrafish Dnm2a-v1 and Dnm2a-v2 compared to 
human DNM2. The PRD domain of Dnm2a-v2 is 102 aa longer than Dnm2a-v1 (black arrow), showing greater 
similarity with human DNM2.
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Figure 2. WISH and double-staining of dnm2a and myf5. WISH shows that dnm2a transcripts are present in 
the CNS and tail of zebrafish embryos from early somitogenesis (11 hpf approximately) to 30 somites stage (24 
hpf). (A) At the 15-somite stage dnm2a is present in the tail (somites, s), at the midbrain/hindbrain boundary 
(mhb) and, bilaterally, at the two otic vesicles (ov). (B) At 24 hpf, dnm2a is present in newly formed somites 
and appears to be declining in intensity at the midbrain/hindbrain boundary. (C) WISH shows dnm2a signal 
in CNS, in embryos at 15 somites stage, more pronounced in the midbrain/hindbrain boundary and in the 
two bilateral otic vesicles (D,E). (F) The expression of dnm2a is diffuse in the neural tube, and more intense 
in the periventricular and in the dorso-lateral portion (black arrowhead). (G) Double-staining reveals dnm2a 
and myf5 at the 15 somite stage: dnm2a appears (in dorsal view of flat mounted embryo dnm2a in somites) 
posteriorly and close to the notochord (black arrowhead) overlapping to some extent with myf5 (white 
arrowhead); in cross section (H), dnm2a is present in the medio-ventral part of the somite and in several adaxial 
cells (black arrowhead), while myf5 is expressed in medial cells (white arrowhead).
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target the splice site between intron 5 and exon 6 (I5E6dnm2a-MO) causing a frame-shift and introducing an 
early down-stream stop codon (Supplementary Fig. 3). We tested both MOs at a range of concentrations (from 
0.16 pmol/embryo to 0.96 pmol/embryo) and observed dose-dependent phenotypic classes (Supplementary 
Fig. 4). In all experiments, MO-injected embryos were compared to embryos at the same developmental stage 
injected with the same amount of a non-specific standard MO (STD-MO). We observed similar phenotypes 
when ATGdnm2a and I5E6dnm2a MOs where injected separately at different concentrations. In order to produce 
optimal numbers of normal-appearing embryos with a conserved overall somite structure, we injected (based on 
our preliminary injections at different concentrations) ATGdnm2a-MO at a concentration of 0.64 pmol/embryo 
and I5E6dnm2a-MO at a concentration of 0.32 pmol/embryo. At these concentrations, 361 embryos injected with 
ATGdnm2a-MO (49% of total) had normal-appearing morphology with completely formed somites (pertaining 
therefore to the C1 class, Fig. 3A, particular), 243 (33% of total) had partially disrupted somites (C2 class, Fig. 3A, 
particular) and 132 (18%) had unformed or totally disrupted somites (C3 class, Fig. 3A, particular); while 342 
embryos injected with I5E6dnm2a-MO were belonging to the C1 class (48% of total), 292 embryos to the C2 class 
(41% of total), and 78 embryos to the C3 class (11% of total).
We assessed MO efficiency in C1 embryos by analysing Dnm2a protein levels by Western blot. We found that 
both morpholinos greatly reduced the intensity of the Dnm2a band (Supplementary Fig. 5) while the BIN1 and 
actin (internal controls) bands were of normal intensities.
Morphologically altered phenotype is specifically linked to dnm2a gene knockdown. To test the 
specificity of ATGdnm2a-MO and I5E6dnm2a-MO, we co-injected low doses of both morpholinos (0.10 pmol/
embryo of each), and evaluated morphologic alterations in embryos at 3 dpf.
We first injected separately 0.10 pmol/embryo of ATGdnm2a-MO, and found 63 embryos (94% of total) 
belonging to the C1 class, 3 embryos (5% of total) to the C2 class, and 1 embryo (1%) to the C3 class. By injecting 
Figure 3. Morphological analysis and quantifications of morpholino-injected embryos. (A) Morphological 
features of STD-MO (ctrl) and morphants, observed under DMR microscope and subdivided into classes 
according to somite appearance: C1 completely formed, C2 partially disrupted, C3 unformed or totally 
disrupted somites (morphological features of ATGdnm2a-MO and I5E6dnm2a-MO-injected embryos are 
overlapping and representative images are shown). (B left) Toluidine blue-stained transverse and longitudinal 
sections at 4 dpf show evident muscle fibre disorganization in ATGdnm2a-MO and I5E6dnm2a-MO-injected 
embryos compared to STD-MO. Scale bar = 20 μ m. (B right) Electron micrographs of longitudinal sections 
show myofibrils less regularly arranged, abundant membranous structures, vesicles and tubules (asterisks) in 
ATGdnm2a-MO and I5E6dnm2a-MO-injected embryos, compared to STD-MO. Scale bar = 1 μ m.  
(C) Quantitation of central nuclei per fibre shows significantly more central nuclei in ATGdnm2a-MO and even 
more in I5E6dnm2a-MO-injected embryos than STD-MO. (D) Quantitation of fibre diameter indicates that 
the distribution of fibre diameters is shifted towards larger diameters in ATGdnm2a-MO and I5E6dnm2a-MO-
injected embryos compared to STD-MO. Morphological analysis were performed on 6 embryos for each group 
(ATGdnm2a-MO, I5E6dnm2a-MO and STD-MO), chosen randomly from 6 independent injections.
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0.10 pmol/embryo of I5E6dnm2a-MO, 57 embryos (77% of total) belonged to the C1 class, 15 embryos (20% of 
total) to the C2 class, and 3 embryos (3% of total) to the C3 class. When low doses of the ATGdnm2a-MO and 
I5E6dnm2a-MO were co-injected in the same embryo, we observed 23 embryos (26% of total) belonging to the 
C1 class, 41 embryos (47% of total) belonging to the C2 class, and 24 embryos (27% of total) belonging to the C3 
class. As control we injected 0.10 pmol/embryo of STD-MO, observing 57 embryos belonging to C1 class (94% 
of total), 4 embryos belonging to C2 class (6% of total) and none embryo belonging to C3 class (Supplementary 
Fig. 6).
These results showed that, when combined, the morpholinos could cause severe morphological alterations 
even at doses that were negligible on their own, confirming their targeting specificity.
Touch evoked response test in embryos after dnm2a knockdown. We performed the touch 
evoked response test in 3 dpf embryos belonging to the C1 class after injection with either ATGdnm2a-MO or 
I5E6dnm2a-MO. This test involves observing an embryo’s swimming behaviour in response to tactile stimula-
tion. In comparison to STD-MO injected embryos, ATGdnm2a-MO morphants presented either almost total 
absence of escape contraction or, more often, they weakly flexed; I5E6dnm2a-MO embryos always displayed 
a weak escape contraction, followed by slow swimming and moving for only a short distance (Supplementary 
Videos 1–3).
Morphological abnormalities in muscles after dnm2a knockdown. We studied larvae at 4 dpf, when 
muscle formation was complete, after conclusion of the two myogenic waves15–17. Toluidine blue-stained trans-
verse and longitudinal sections showed evident muscle fibre disorganization in MOs-injected embryos compared 
to STD-MO controls (Fig. 3B). Similarly, longitudinal section electron micrographs revealed altered myofibril 
organization, abundant membranous structures and prominent vesicles and tubules, in MOs-injected embryo 
muscle compared to control muscle (Fig. 3B).
Toluidine blue-stained transverse sections (0.4 μ m thick), taken from the trunk-tail region had significantly 
greater numbers of central nuclei per muscle fibres in morphants than controls (ATGdnm2a-MO: 0.12 ± 0.02; 
I5E6dnm2a-MO: 0.13 ± 0.04; STD-MO: 0.06 ± 0.004; p = 0.003 and p = 0.0002 respectively) (Fig. 3C). Muscle 
fibre diameters were also significantly larger than those in control embryos (fibres 10.1 μ m or larger were: 28.1% 
in ATGdnm2a-MO vs. 10.7% in STD-MO, and 42.7% in I5E6dnm2a-MO vs. 10.7% in STD-MO; p = 0.0006 
and p < 0.0001 respectively; Chi Square test). There were also significantly fewer fibres per transverse section in 
ATGdnm2a-MO embryos compared to STD-MO (ATGdnm2a-MO: 173.10 ± 5.97 vs. STD-MO: 223.0 ± 14.99; 
p = 0.009); while in I5E6dnm2a-MO embryos the number of fibres per transverse section was not significantly 
different from STD-MO embryos (I5E6dnm2a-MO: 178.5 ± 8.84 vs. STD-MO: 223.0 ± 14.99; p = 0.621) 
(Fig. 3D).
Rescue of dnm2a knockdown embryos by expression of dnm2a-v1 and dnm2a-v2. In order to 
demonstrate that the defects observed in dnm2a morphants were specifically due to protein reduction induced by 
the ATGdnm2a-MO or I5E6dnm2a-MO, we performed rescue experiments in dnm2a knocked down embryos. 
We injected the two dnm2a spliced isoforms, the one previously reported, lacking a complete PRD domain, and 
the one we had found.
For ATGdnm2a knockdown rescue, one-cell stage embryos were co-injected with ATGdnm2a-MO 
(0.64 pmol) and either dnm2a-v1 mRNA or dnm2a-v2 mRNA. At 3 dpf, the proportion of embryos with wild type 
phenotype was greater and the proportions with partially disrupted somites, and unformed or totally disrupted 
somites, were smaller with both rescue mRNAs compared to those injected with ATGdnm2a-MO alone (Fig. 4A,a).
The touch evoked escape test, performed in embryos with non-altered somites, showed that the percentage of 
embryos that moved normally increased from 18%, when injected with ATGdnm2a-MO, to 27% with injection 
of dnm2a-v1 (p = 0.0456), and to 52% with injection of dnm2a-v2 (p < 0.001). Comparison of dnm2a-v1 vs. 
dnm2a-v2 injection, showed a significantly greater rescue with the latter (p = 0.0126) (Fig. 4A,b).
To further assess muscle rescue in ATGdnm2a-MO zebrafish larvae we performed birefringence analysis18 
finding that the positions of fibres in somites appeared more regular after injection of dnm2a-v1, and more so 
after injection of dnm2a-v2 in comparison to embryos injected with ATGdnm2a-MO alone (ATGdnm2a-MO vs. 
dnm2a-v1, p = 0.01; ATGdnm2a-MO vs dnm2a-v2, p = 0.0002). Comparison of dnm2a-v1 vs. dnm2a-v2 injec-
tion showed that the increase in birefringence with the latter was significantly greater (p = 0.0001) (Fig. 4A,c and d).
For I5E6dnm2a knockdown rescue, one-cell stage embryos were co-injected with I5E6dnm2a-MO 
(0.32 pmol) and either dnm2a-v1 mRNA or dnm2a-v2 mRNA (400 pg each). Like for the ATGdnm2a-MO, at 
3 dpf the proportion of embryos with wild type phenotype was greater, and the proportions of embryos with 
partially disrupted and unformed or totally disrupted somites were smaller, when rescue mRNAs were used 
(Fig. 4B,a). The touch evoked escape test, also performed in embryos with non-pathological somites, showed 
that the percentage of embryos that moved normally increased from 37% to 43% with injection of dnm2a-v1 
(p = 0.02), and to 49% with injection of dnm2a-v2 (p = 0.002) (Fig. 4B,b); while comparison between dnm2a-v1 
vs. dnm2a-v2 rescued embryos failed to show any significant difference (p = 1). Birefringence analysis showed 
that in embryos rescued with dnm2a-v1 or dnm2a-v2 there was a significant increase in birefringence compared 
to I5E6dnm2a-MO injected alone embryos (I5E6dnm2a-MO vs. dnm2a-v1, p < 0.0001; and I5E6dnm2a-MO vs. 
dnm2a-v2, p < 0.0001), and that there was no significant difference when comparing dnm2a-v1 vs. dnm2a-v2 
rescued embryos (p = 0.9215) (Fig. 4B,c and d).
Dose-dependent motility defects in embryos administered mutated human DNM2 mRNA. We 
injected one-cell embryos with either DNM2 mRNA containing the R522H mutation that causes CNM, DNM2 
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mRNA containing the G537C mutation that causes CMT, or wild-type DNM2 mRNA. The R522H mutation was 
obtained from a patient’s cDNA; the G537C mutation was obtained by mutagenesis. We assessed embryos after 
injecting increasing quantities (from 50 pg/embryo to 600 pg/embryo) of WT and mutated mRNAs, and found 
that 24 hpf mortality was dose-dependent (Data not shown). The frequency of surviving embryos was higher at 
every tested concentration in WT mRNA injected embryos compared to mutated mRNAs injected embryos. In 
order to have greater numbers of embryos with less severe movement defects suitable for our analyses, we chose 
to inject 200 pg of mRNA (Supplementary Fig. 7).
We found that movements in response to touch stimulus in surviving embryos at 48 hpf were altered, and 
alterations depended on the type of mRNA injected. After injection of 200 pg CNM mRNA, 75% (n = 128) of sur-
viving embryos had altered touch responses; after injection of 200 pg CMT mRNA 73% (n = 132) of embryos had 
altered touch responses; after injection of 200 pg wild-type mRNA, only 12.2% (n = 130) had altered responses. 
The type of movement alterations observed in embryos injected with CNM mRNA, consisted in weak contraction 
that produced a circular instead of a linear escape trajectory. In embryos injected with CMT mRNA motion was 
severely impaired and characterized by instantaneous overturning of the animal without escape (Supplementary 
videos 4–6).
Figure 4. (A) Rescue with dnm2a-v1 and dnm2a-v2 after injection of ATGdnm2a-MO. (a) Appearance of 
embryos at 3 dpf after injection of ATGdnm2a-MO and either dnm2a-v1 or dnm2a-v2 rescue. The proportion 
of normal-appearing embryos (C1) is greater after rescue with dnm2a-v1 and dnm2a-v2 than after treatment 
with ATGdnm2a-MO alone. (b) Touch evoked response test results in normal-appearing embryos (C1) 
identified in experiments performed in (a). The percentage of embryos with normal touch evoked response was 
significantly greater in touch evoked after rescue with dnm2a-v1 and dnm2a-v2 than embryos injected with 
ATGdnm2a-MO alone (results obtained from 5 indipendent experiments). (c) Analysis of birefringence at 3 dpf 
in n = 3 somites after the end of the yolk in 6 independent replicates. Birefringence is evident in the muscle of 
STD-MO embryos, reduced in somites of ATGdnm2a-MO embryos and reverted to almost normal in embryos 
rescued with dnm2a-v1 and dnm2a-v2. (c) Graph shows quantitation of birefringence in STD-MO embryos, 
ATGdnm2a-MO embryos, embryos rescued with dnm2a-v1 and embryos rescued with dnm2a-v2. (B) Rescue 
with dnm2a-v1 and dnm2a-v2 after injection of I5E6dnm2a-MO. (a) Appearance of embryos at 3 dpf after 
injection of I5E6dnm2a-MO and either dnm2a-v1 or dnm2a-v2 rescue. The proportion of normal-appearing 
embryos (C1) is greater after rescue with dnm2a-v1 and dnm2a-v2 than after treatment with I5E6dnm2a-MO 
alone. (b) Touch evoked response test results in normal-appearing embryos (C1) identified in experiments 
performed in (a). The percentage of embryos with normal touch evoked response was significantly greater in 
touch evoked after rescue with dnm2a-v1 and dnm2a-v2 than embryos injected with I5E6dnm2a-MO alone 
(results obtained from 4 independent experiments). (c) Analysis of birefringence at 3 dpf in n = 3 somites after 
the end of the yolk in 6 independent replicates. Birefringence is evident in the muscle of STD-MO embryos, 
but significantly reduced in somites of I5E6dnm2a-MO embryos and reverted to almost normal in embryos 
rescued with dnm2a-v1 and dnm2a-v2. (c) Graph shows quantitation of birefringence of STD-MO embryos, 
I5E6dnm2a-MO embryos, embryos rescued with dnm2a-v1 and embryos rescued with dnm2a-v2.
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Morphological studies on embryos administered mutated human DNM2 mRNA. To determine 
morphological correlates of motility defects, we used monoclonal antibodies znp-1 and zn-5, and α -bungarotoxin 
(α -btx) staining to detect primary motor axons, secondary motor axon projections, and acetylcholine receptors 
(AChRs) at neuromuscular junctions, respectively, in 48 hpf embryos19–21.
By confocal microscopy, primary motor axons in embryos administered with wild-type mRNA showed nor-
mal migration and extension along common axonal trajectories, and the overlap between znp-1 and α -btx, was 
similar to that in non-injected embryos. In embryos injected with CMT or CNM mRNA, primary motor axons 
migrated normally along the common path, but minor defects in pathfinding and in shape after the choice point 
were evident (Fig. 5A). Furthermore, a reduced presence of α -btx-positive spots was detected in both groups of 
embryos (Fig. 5A). Densitometric quantitation confirmed that the α -btx-positive spots were significantly reduced 
(p < 0.0001 for both CNM and CMT; Chi Square test) compared to controls (Fig. 5B).
By confocal microscopy, secondary motor axons, in embryos injected with the wild-type DNM2 mRNA, 
migrated normally and completely along the common path, in a similar way to neuronal migration in 
non-injected embryos (data not shown). However, defects were evident in embryos injected with CNM or CMT 
mRNAs (Fig. 6A). In particular, in embryos expressing CNM mRNA, although axons appeared to correctly exit 
the spinal cord and migrate to the periphery, branching was rare (Fig. 6A,b). In embryos expressing CMT mRNA, 
secondary motor axons were completely absent (Fig. 6A,c).
We examined muscles from the trunk-tail region in larvae at 4 dpf injected with CNM, CMT or control 
mRNAs. Toluidine blue-stained transverse sections (0.4 μ m thick) showed that in both CNM- and CMT-injected 
embryos, muscle tissue had a more disordered morphology than controls, with fibres of variable size, frequent 
lobular appearance, and more space surrounding fibres (Fig. 7A). Electron micrographs appeared to show greater 
vesicular decoration in spaces surrounding fibres and less orderly morphology compared to control embryos 
(Fig. 7A).
Numbers of central nuclei per total number of fibres were significantly greater in CNM- (0.10 ± 0.01; 
p = 0.030) and CMT- (0.11 ± 0.01; p = 0.022) injected embryos than controls (0.07 ± 0.005). Total numbers of 
fibres per section were not significantly lower after CNM injection (242.9 ± 12.91; p = 0.103), but were signif-
icantly fewer after CMT injection (202.1 ± 19.47; p = 0.008) relative to control (273.4 ± 11.57). Fibre diameter 
(Fig. 7B) was also significantly greater in CNM and CMT embryos than control (fibre diameters of 10.1 μ m or 
greater were 30.2% and 17.3% in CNM and CMT, respectively, compared to 13.3% in controls, p < 0.0001).
Discussion
Recent years have seen substantial advances in our understanding of centronuclear myopathy and Charcot Marie 
Tooth dominant intermediate type B diseases; however little is known about overlapping aspects of these two 
pathologies.
For this reason, the rapid zebrafish in vivo model appeared as a useful analytical tool to investigate the effects 
of dynamin-2 mutations on the neuromuscular system in CNM and CMT.
To be able to fully understand dynamin 2-related disorders in zebrafish, we first silenced dnm2a using two 
different morpholinos, one directed against the start site of the dnm2a transcript (ATGdnm2a knockdown), and 
Figure 5. Primary motor neurons (znp-1) and AChRs (α-btx) in human mRNAs injected embryos. (A) Co-
localization of markers for primary motor neurons (znp-1) and AChRs (α -btx) in 5 spinal hemisegments and 
somites, in 48 hpf zebrafish embryos. The images are representative of those found in n = 10 embryos for each 
condition, during 3 distinct experiments. In DNM2_mutCNM-injected embryos (d,e) and DNM2_mutCMT-
injected embryos (g,h) primary motor axons migrate normally along the common path (compare a with d and g) 
with slight pathfinding and shape defects after the choice point (arrows). The merge images suggest that 
DNM2_mutCNM- and DNM2_mutCMT-injected embryos present fewer α -btx-positive spots than DNM2-
controls, with the co-localization signal is reduced in intensity (f,i), compared to control (c), even though znp-1 
and α -btx signals co-localize correctly (arrowhead in the enlargement, scale bar = 25 μ m). Scale bar = 20 μ m. 
(B) Quantification of α -btx-positive spots in n = 10 complete embryos for each condition. DNM2_mutCNM 
and DNM2_mutCMT- injected embryos present fewer α -btx-positive spots than controls. Error bars are SEMs. 
Scale bar = 20 μ m.
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one that targeted the splice site between intron 5 and exon 6 (I5E6dnm2a knockdown). ATGdnm2a knockdown 
resulted in severe abnormalities of the muscular system in zebrafish, similar to those documented previously10, 
while I5E6dnm2a knockdown induced different motility defects, although morphological features were similarly 
altered in both ATGdnm2a and I5E6dnm2a knockdown.
We then introduced in zebrafish embryos DNM2 transcripts containing mutations that cause CNM or CMT 
in humans. This is a most novel aspect of our study that, taking advantage of the high identity between the human 
and zebrafish dynamin-2 proteins, allowed us to mimic the patient situation in which both the wild-type and 
the pathological allele are present. Since many human dynaminopathies are autosomal dominant and ascribed 
to gain of function of the aberrant protein6, our model promises to be useful for investigating mechanisms of 
Figure 6. Secondary motor neurons (zn-5) in embryos injected with human mRNAs. (A)Visualization 
of secondary motor neurons by zn-5 monoclonal antibody-labelling of 48 hpf zebrafish embryos. By 48 hpf 
secondary motor neurons have completed their migration along the common path, and axons of the ventral 
nerve extend to the ventral myotome in both wild-type embryos (not shown) and those injected with wild-
type DNM2 mRNA (DNM2_ctrl) (a). However in DNM2_mutCNM embryos, secondary motor neuron axons 
appear to exit the spinal cord and migrate to the periphery, but branching is rare (b). By contrast, in embryos 
expressing DNM2_mutCMT secondary motor axons are not observed (c). Scale bar = 10 μ m. The images are 
representative of those found in average12 embryos for each condition, during 3 independent experiments. (B) 
Graph shows quantitation of branchings.
Figure 7. Morphological analysis and quantifications of human mRNAs injected embryos. (A) Toluidine 
blue-stained transverse sections and electron micrographs at 4 dpf of DNM2_mutCNM and DNM2_mutCMT 
-injected embryos in comparison to control (DNM2_ctrl). In Toluidine blue-stained sections both CNM and 
CMT injected embryos muscle tissue has more disordered morphology than control embryos, with fibres of 
variable size, frequent lobular appearance and more space surrounding fibres. Scale bar = 10 μ m. Electron 
micrographs show greater vesicular decoration in spaces surrounding fibres (asterisks) and loose morphology. 
Scale bar = 0.5 μ m. (B) Quantitation of fibre diameter indicates that the distribution of fibre diameter is shifted 
towards larger diameter in CNM- and CMT-injected embryos compared to control (in DNM2_mutCNM 
and DNM2_mutCMT 30.2% and 17.3% respectively of fibre diameters were 10.1 μ m or greater, compared to 
13.3%in control p < 0.0001). (C) Quantitation of central nuclei per fibre shows significantly more central nuclei 
in both CNM- and CMT-injected embryos than control. Morphological analysis were performed on n = 6 
embryos for DNM2_mutCNM, DNM2_mutCMT and DNM2_ctrl each, chosen randomly from 4 different 
injections.
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human dynaminopathies. The introduction of DNM2 transcripts containing mutations that cause CNM or CMT 
in humans, resulted indeed in severe neuromuscular abnormalities in zebrafish embryos similar to some of those 
observed in the human diseases.
Building upon previous work10, novel phenotypes were revealed by comparing two different mutations, one 
causing CNM, and the other causing CMT, both positioned very close in the PH domain of the DNM2 protein. 
Human transcripts with mutations in the PH domain give rise to a variety of disease phenotypes in humans, from 
late onset CNM22 to severe CMT8. Although some overlap of CNM and CMT pathologies has been observed in 
patients with PH domain mutations, no known DNM2 mutation causes both CNM and CMT23–25. Specifically, 
we used mRNA containing the R522H mutation, present in three of our CNM patient cohort with variably severe 
phenotypes. We also used an mRNA containing the G537C mutation, known to cause CMTDIB neuropathy4,26,27.
We found that both mutated transcripts produced morphological defects that primarily involved secondary, 
rather than primary motor neurons.
Similarities between zebrafish secondary motor neurons and those of birds and mammals are greater than 
similarities between the corresponding primary motor neurons28,29. Zebrafish secondary motor neurons are in 
fact similar to human α motor neurons28,30 and thus zebrafish promise to be a useful model for elucidating mech-
anisms of human lower motor neuron disease.
At 48 hpf, zebrafish motor neurons have extended branches to form synapses with laterally located muscle fibres, 
turned laterally at the edge of the myotome, and grown along and innervated myosepta. Between 48 and 72 hpf, 
secondary motor axons extend into the myotome following pathways pioneered by the primary motor axons31–34. 
Introduction of CNM mRNA (containing the R522H mutation) produced mild defects in zebrafish primary motor 
neuron morphology, and severe and obvious defects in secondary motor neuron morphology, resulting in incorrect 
branching of the latter. Introduction of CMTDIB mRNA (containing the G537C mutation) produced defects in 
primary motor neurons similar to those induced by CNM mRNA, while secondary motor neurons were absent.
The touch response test also confirmed that defects in CMT mRNA-injected embryos were more severe compared 
to those injected with CNM mRNA. Furthermore, the significantly lower numbers of fibres per section than controls, 
found in CMT, but not in CNM mRNA injected embryos, are likely to result from more severe defects in innervation/
maturation of muscle in the CMT model. As in human motor neuron diseases, denervation or lack of innervation are 
likely to cause fibre atrophy, while persisting fibres are likely to become hypertrophic as compensatory effect.
Based on our findings, therefore we can conclude that the zebrafish CNM and CMT models show some of the 
characteristics of human centronuclear myopathy and Charcot Marie Tooth neuropathy dominant intermediate 
type B, respectively.
However, these two models also showed some closely similar defects such as the increase in central nuclei per 
total number of fibres, and the increase in fibre diameters, compared to controls. To this regard we note that clini-
cal overlap with CMT has been reported for some CNM patients presenting with a mild peripheral nerve involve-
ment35, and that EMG results in some of the patients described by Bohm et al.25 and Echaniz-Laguna et al.36 were 
suggestive of neuropathy. Only two patients (mother and son) with the G537C mutation (reported in the article 
as G533C, following previous annotation) causing CMT have been reported37. The neuropathy in these patients 
was characterized by mild-to moderate impairment with scarce evolution in middle age, upper limbs relatively 
preserved, and asymmetric involvement of calves affecting muscles of both anterior and posterior compartments.
Primary myopathic features in CMT patients with DNM2 mutations have never been reported, including in 
the two patients with the G537C mutation. Since muscle biopsy is not usually performed in these patients, pres-
ence of central nuclei in muscle fibres cannot be completely ruled out.
With the present study we emphasize that morphometric techniques, normally applied to study histopathol-
ogy in human muscle, can be usefully employed to evaluate muscle histopathology in zebrafish, underlining the 
versatility of this animal model.
Interestingly, working on the zebrafish dynamin-2 gene led us to identify a new dnm2 transcript (dnm2a-v2). 
This is much closer – in terms of length and sequence, to the normal human DNM2 transcript – than the previ-
ously identified transcript (renamed dnm2a-v1). We have shown that dnm2a-v2 is not present before the epiboly 
stage, while dnm2a-v1 is present from the earliest developmental stages11,12. The two isoforms could be both 
developmentally regulated and produced by the zygote; alternatively the long transcript could have a zygotic 
origin, while the short one could be provided maternally12. Computational analysis indicated the presence of a 
longer dnm2a isoform with a complete PRD domain (present partially in the short isoform). To confirm this idea 
with experimental data, we performed rescue analysis on morphants with both dnm2a isoforms. The muscular 
abnormalities were rescued by the introduction of either dnm2a-v1 or dnm2a-v2 transcripts, but the injection of 
dnm2a-v2 produced a greater number of rescued animals (Fig. 4B).
To conclude, our data confirm that the zebrafish dnm2a knockdown is a valuable model for dynaminopa-
thies and, most importantly, demonstrate that overexpression of human DNM2 mRNAs, containing different 
disease-related mutations, cause a continuum of pathological features similarly to what observed in human cen-
tronuclear myopathies and neuropathies. This characteristic allowed us to mimic the patient situation in which 
both the wild-type and the pathological allele are present.
Therefore, zebrafish is a rapid, low-cost and powerful screening tool to address the study of mutational effects 
in vivo to understand the mechanisms underlying DNM2-related diseases, and, possibly, to accelerate the identi-
fication of new therapeutic targets.
Materials and Methods
Animal care. The studies on Zebrafish were approved by the animal ethics committee of the University of 
Milan and carried out at the University facility. Animals were always injected according to the principles of Good 
Animal Practice as defined by Italian animal welfare regulations. The experiments were performed on zebrafish 
(AB strain) embryos and larvae between 1 and 4 days post fertilization (dpf).
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3′RACE. To verify bioinformatics results we performed 3′ RACE experiments, using the following primers:
YZTT: 5′ -caggaaacagctagacTAAGCTTGTCCACG(T)17-3′ 
     Y  Z
Y: 5′ -CAGGAAACAGCTATGAC-3′ 
Z: 5′ -TGACTAAGCTTGTCGACG-3′ 
X0dnm2a: 5′ -GCATCTCATGATCAACAGCG-3′ 
X1dnm2a: 5′ -GACGAGATGCTGAGGATG-3′ 
X2dnm2a: 5′ -AGCACCAGCACCATTTCC-3′ 
X3dnm2a: 5′ -CCAGGATCCTTTCAGCGC-3′ 
R: 5′ -GTCCTCGGCGTGCTTTGGC-3′. 
First amplification was carried out with primers X0 and Z with 1 μ l of X0/Y PCR mixture as template. The 
conditions were 95 °C for 2 min, 52 °C for 10 sec, and 72 °C for 1 min (1 cycle) and 95 °C for 5 sec, 52 °C for 10 sec, 
and 72 °C for 1 min (33 cycles). Seminested PCR with primers Z1.2N and Z were necessary to obtain sufficient 
specific cDNA for cloning and sequencing.
RT-PCR. Total RNA was extracted from zebrafish embryos at different stages, or from human muscle biopsies 
using TRI Reagent (MRC, Cincinnati, OH, USA). First-strand cDNA synthesis reaction from total RNA was 
catalyzed by Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostic, Penzberg, Germany). cDNA was 
amplified with specific primers using Phusion High-Fidelity polymerase (Finnzymes, Thermo Fisher Scientific, 
Waltham, MA, USA). The PCR products were purified using Illustra ExoProStar (GE Healthcare, Life Sciences, 
WI, USA) and sequenced directly with BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Life 
Technologies, Carlsbad, CA, USA). Sequences were analyzed on an ABI Prism 3100 Genetic Analyzer (Applied 
Biosystems, Life Technologies, Carlsbad, CA, USA).
The primers used to clone the cDNA in the vector were:
dnm2a-v1: 5′ -TACAACACATGCGCGTCTTC-3′ (Forward) and 5′ -CAACGACAGCTGGATACCTG-3′ 
( R e v e r s e ) ;  d n m 2 a - v 2 :  5 ′  - C C T C T G A T C A C A G C A C G TA T T - 3 ′   ( F o r w a r d )  a n d 
5′ -TAAGTGTCCTCTGACCAGCG-3′ (Reverse); human-DNM2: 5′ -GGGAGCAACGGCTACAGAC-3′ 
(Forward) and 5′ -CCCAGACCACTGAAGCTCCT-3′ (Reverse).
The pr imers  for  RT-PCR analysis  of  v1 and v2 isoform expression were:  dnm2a-v1: 
5′ -CGTATTACAACACATGCGCG-3′  (Forward) and 5′ -catgcgtgccaaagaatagga-3′  (Reverse), with 
the reverse primer designed on the 3′ UTR, which is different for the v1 and the v2 isoform; dnm2a-v2: 
5′ -CCTCTGATCACAGCACGTATT-3′ (Forward) and 5′ -TAAGTGTCCTCTGACCAGCG-3′ (Reverse).
In situ hybridization. Whole-mount RNA in situ hybridization was carried out using probes made by 
in vitro transcription with T7 or SP6 RNA polymerase (Promega Corporation, Madison, WI, USA). Templates 
were generated by PCR using the following primers: 5′ -GTCTAATCCTTGCCGTCACC-3′ (Forward, SP6), and 
5′ -TAAGAACTTCCGCCCAGATG-3′ (Reverse, T7), common to the v1 and v2 isoforms. PCR was performed 
on cDNA from 1 dpf wild-type embryos. The probe and template sequences were verified.
For histological analysis, stained embryos were fixed in 4% paraformaldehyde, dehydrated, wax embedded, 
sectioned (8 μ m) with microtome (Leitz 1516) and stained with eosin. Images were taken with an Olympus BH2 
microscope, equipped with a Leica DFC 320 digital camera and IM50 software (Leica).
Morpholino injections. For dnm2a knockdown, the following morpholinos were designed and pur-
chased, along with standard control morpholino, from Gene Tools (Gene Tools, Philomath, OR, USA): 
5′ -ACctacgacaagggaaaaatcacat-3′ (I5E6dnm2a-MO) and 5′ - ctcgggttactttcaagtgttcag-3′ (ATGdnm2a-MO).
Fertilized eggs were collected after timed mating of adult zebrafish and injected at the 1 – 2-cell stage 
using an Eppendorf transferman nk2 micromanipulator (Eppendorf). Embryos were injected with either 
I5E6dnm2a-MO (0.32 pmol/embryo) or ATGdnm2a-MO (0.64 pmol/embryo) or morpholino (to verify absence 
of morpholino-mediated toxicity) in a volume of 4 nl.
For rescue experiments, embryos were co-injected (total volume 4 nl) with ATGdnm2a-MO morpholino plus 
either v1-isoform_mRNA (200pg) or v2-isoform_mRNA (200pg) and with I5E6dnm2a-MO morpholino plus 
either v1-isoform_mRNA (400pg) or v2-isoform_mRNA (400pg).
Morpholinos were diluted in Danieau solution38. Rhodamine dextran (Molecular Probes, Life Technologies, 
Carlsbad, CA, USA) was usually co-injected as tracer to enable monitoring with a Leica MZ FLIII epifluorescence 
microscope equipped with a Leica DCF 480 digital camera and IM50 software (Leica).
After injection, embryos were allowed to develop in fish water at 28 °C up to the stage of interest.
Western Blot. Dechorionated embryos (minimum 20 per experiment) were solubilized in RIPA buffer 
(Radio-Immunoprecipitation Assay buffer) plus protease inhibitor and phenylmethylsulfonyl fluoride,100X 
(PMSF). Samples were boiled for 10 min at 95o or sonicated. Thirty μ g of protein samples were electrophoresed 
on 10% SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA) 
following standard procedures. The membranes were blocked with 5% nonfat dry milk in TBS, pH 7.5, contain-
ing 0.1% Tween 20 (TBST) for 1 h at room temperature and subsequently incubated with the primary antibodies 
anti-DNM2 (1:50, polyclonal, Santa Cruz Biotecnology, Santa Cruz, CA, USA), anti-BIN1 (1:500, polyclonal, 
Bethyl Laboratories, Montgomery, USA) and anti-acetylated α -tubulin (1:3000, polyclonal, Sigma-Aldrich, Saint 
Louis, MO, USA), the latters used as internal control, followed by biotinylated goat anti-rabbit, ABC-Kit Complex 
(DAKO, Agilent Technologies, Santa Clara, CA, USA), and ECL detection (Bio-Rad Laboratories, Hercules, CA, 
USA).
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Whole-mount immunohistochemistry and AChR labelling. All antibodies were diluted in block-
ing solution (5% w/v bovine serum albumin [BSA] in phosphate buffered saline [PBS] with 0.1% Tween20). 
After overnight fixation in 4% paraformaldehyde at 4 °C, the embryos were washed 5 times for 5 min in 0.1% 
PBS-Tween, rinsed in water, permeabilized for 15 min in cold acetone, rinsed in water, washed 5 times for 5 min 
in 0.1% PBS-Tween, incubated in NH4Cl solution for 30 min at room temperature, blocked for 3 h at room tem-
perature in blocking solution and, finally, incubated overnight at 4 °C with primary antibody. The next day, the 
embryos were washed 5 times for 10 min in 0.1% PBS-Tween, then every 2–3 h with blocking solution at room 
temperature on an orbital shaker until evening, when secondary antibody was applied overnight at 4 °C, followed 
by washings (3 times for 5 min) in 0.1% PBS-Tween at room temperature. Primary antibodies were: anti-Znp-1 
1:200 (mouse anti-syt2b, anti-synaptotagmin 2) or anti-Zn-5 1:200 (mouse anti-alcama, activated leucocyte cell 
adhesion molecule A), both from Zebra International Resource Center (OR, USA); the secondary antibodies 
were: Alexa 488-conjugated goat anti-mouse IgG or Alexa 546-conjugated goat anti-rabbit IgG, (Invitrogen Life 
Technologies, Carlsbad, CA, USA) both diluted 1:200.
Alpha-bungarotoxin (α -btx) labeling was performed as described elsewhere39. Briefly, after incubation with 
primary and secondary antibody, embryos were incubated for 30 min at room temperature in 10 g/ml Alexa 
547-conjugated α -btx (Sigma-Aldrich, Saint Louis, MO, USA), diluted in BSA-PBS-Triton (5% normal bovine 
serum, and 1% Tween in PBS-Triton), washed in PBS-Triton, and mounted in Mowiol.
Confocal microscopy was performed on a Leica TCS SP2 AOBS microscope, equipped with an argon laser 
(Leica).
Muscle structure and ultrastructure. Zebrafish at 4 dpf were fixed 2 h in 2.5% glutaraldehyde-sodium 
phosphate buffer, pH 7.4; left in buffer overnight at 4 °C. The embryos were post-fixed in phosphate-buffered 
2% OsO4, dehydrated in graded ethanol, and embedded in epoxy resins (Electron Microscopy Sciences, Hatfield, 
Pennsylvania). Semi-thin sections (0.4 μ m thick) were examined by light microscopy after staining with toluidine 
blue. Ultrathin sections of zebrafish tails were collected onto grids, stained with uranyl acetate and lead citrate, 
and examined with a FEI electron microscope.
Quantitation. To quantify the α -bungarotoxin (α -btx) level, the red signal area (expressed as arbitrary units 
that corresponded to number of pixels) was calculated on each confocal z-stack by means of Fiji software version 
2.0 (http://rsb.info.nih.gov/nih-image/) on micrographs taken at same exposure conditions40. Briefly, fields occu-
pied by the entire tail of the animal were photographed from each z-stack and digitalized. Using the software, a 
threshold was applied to the photographs to obtain red and black images with areas positive for α -btx in red and 
negative areas in black. The area positive for α -btx was calculated as a percentage of the entire image on each con-
focal z-stack, and the mean percentage calculated. The same procedure was repeated for each group of animals, 
and the mean percentage calculated.
Muscle fibres and central nuclei were counted on micrographs of toluidine blue-stained semithin sections 
reproducing the whole cross-sectional area of the fish in the region immediately after the yolk, taken at 63X under 
a Zeiss Axioplan2 microscope. Determination of muscle fibre diameters was obtained using Microscope Software 
AxioVision Release 4.8.2 (Zeiss, Oberkochen, Germany).
Human cDNA. Total RNA was extracted from skeletal muscle using TRI Reagent (MRC, Cincinnati, OH, 
USA). First-strand cDNA synthesis reaction from total RNA was catalyzed by Transcriptor First Strand cDNA 
Synthesis Kit (Roche Diagnostic, Penzberg, Germany). cDNA was amplified with specific primers using Phusion 
High-Fidelity polymerase (Finnzymes, Thermo Fisher Scientific, Waltham, MA, USA). The PCR products were 
purified and sequenced directly with BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Life 
Technologies, Carlsbad, CA, USA). Sequences were analyzed on an ABI Prism 3100 Genetic Analyzer (Applied 
Biosystems, Life Technologies, Carlsbad, CA, USA). Results were compared to the human cDNA DNM2 database 
sequence NM_001005360.1.
Mutagenesis. Mutagenesis of wild-type human DNM2 was performed using the QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). To introduce the CMTD1B mutation 
(c.1610G > T) the following primers were designed: 5′ -GCCTGATGAAAGGCGTCTCCAAGGAGTACTGG-3′ 
and 5′ -CCAGTACTCCTTGGAGACGCCTTTCATCAGGC-3′ . After the reaction, sequences were cloned by 
transforming XL1-Blue Competent Cells from STRATAGENE (Agilent Technologies, Santa Clara, CA, USA). 
All sequences were confirmed using an ABI Prism 3130XL Genetic Analyzer. For RNA injection, plasmids were 
linearized with NotI and transcribed using the SP6 mMessage Machine kit (Ambion, Life Technologies, Carlsbad, 
CA, USA).
Plasmid construction. The cDNAs of full-length human DNM2 and zebrafish dnm2a were amplified by 
RT-PCR using total RNA extracted from human muscle or whole zebrafish embryos. The primer sequences 
used were 5′ - TCCATCGATGGGAGCAACGGCTACAGAC -3′ (sense primer plus ClaI sequence) and 5′ - 
AGCTCTAGACCCAGACCACTGAAGCTCCT -3′ (antisense primer plus XbaI sequence) for Human cDNA, 
and 5′ -GAATTCGAGAGACGGCCAGAAACCAT-3′ (sense primer in common for v1 and v2 isoform plus 
EcoRI sequence), 5′ -CTCGAGCAGGTATCCAGCTGTCGTT-3′ (antisense primer for v1 isoform plus XhoI 
sequence) and 5′ -CTCGAGCGCTGGTCAGAGGACACTTA-3′ (antisense primer for v2 isoform plus XbaI 
sequence) for zebrafish dnm2a cDNA. The amplified fragments were inserted into pCS2+ vector (Clontech, 
Takara Bio Inc., Otsu, Shiga, Japan). After digestion of pCS2+ vector with appropriate restriction enzymes, iso-
lated cDNA of DNM2 or dnm2a was cloned into the pCS2+ vector (Clontech, Takara Bio, Otsu, Shiga, Japan). 
The following constructs were established: pCS2+ -DNM2, pCS2+ -dnm2a-v1 isoform, pCS2+ -dnm2a-v2 
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isoform. The cells used were Library DH5-alpha (Invitrogen Life Technologies, Carlsbad, CA, USA). Enzymes 
used were: ClaI and XbaI (New England biolabs, Ipswich, MA), and EcoRI and XhoI (Promega Corporation, 
Madison, WI, USA).
RNA injection of zebrafish embryos. Zebrafish embryos were injected as described41. Briefly, fertilized 
eggs were injected at the one- to two-cell stage using a Microinjector (Leica). Embryos were injected with Human 
DNM2 mRNA (200 pg and 400 pg) or zebrafish dnm2a mRNA (200 pg and 400 pg) in a 4 nL volume. Plasmids 
were linearized with NotI enzyme (New England Biolabs, Ipswich, MA, USA).
Screening for embryonic motility. At 3 dpf embryos were subjected to a tactile stimulus. Using a needle, 
a gentle stimulus was applied at the tail of the larvae and its reaction observed. Wild-type larvae at this stage of 
development have a normal activity. Upon application of the tactile stimulus they swim away from the source of 
the stimulus42.
Birefringence. Zebrafish at 3 dpf were observed after anesthesia using 0.016% tricaine (Ethyl 
3-aminobenzoate methanesulfonate salt (Sigma-Aldrich, Saint Louis, MO, USA) in fish water as described 
previously43. For quantitation, the area occupied by 3 somites positioned immediately after the end of the yolk 
was selected and the average grey value of the pixels in this area measured by the software Fiji. This procedure 
was repeated three times and the average calculated for each embryo. Muscle birefringence was analysed for 6 
embryos in each group.
Statistical Analysis. Results were expressed as means ± standard deviation. Differences between fibre diam-
eters and between central nuclei (ATGdnm2a-MO and I5E6dnm2a-MO vs STD-MO and DNM2_mutCNM and 
DNM2_mutCMT vs DNM2_ctrl) were assessed using the Chi Square test, and differences between groups in 
rescue experiments (ATGdnm2a-MO, I5E6dnm2a-MO, dnm2a-v1 isoform, dnm2a-v2 isoform and STD-MO), 
were assessed by the two-tailed Student T test or one-way ANOVA with post-hoc Dunnet test, where appropri-
ate. Differences between DNM2_CMT or DNM2_CNM and DNM2_CTRL were assessed by two-tailed Student 
t-test. P values were considered significant: *p ≤ 0.05, **p ≤ 0.01; ***p ≤ 0.001.
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